VERA GARNETT: Open Payments
NPI 1619518206 · GLEN BURNIE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$740 in 8 payments from 8 companies in 2025. Trend: 2023 $327 · 2024 $992 · 2025 $740
Food & beverage: $740
| Company | Payments | Amount |
|---|---|---|
| CeQur Corporation | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Amgen Inc. | 1 | $122 |
| Actelion Pharmaceuticals US, Inc. | 1 | $104 |
| Novo Nordisk Inc | 1 | $95 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $91 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $71 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: CeQur Simplicity, REXULTI, TAVNEOS, UPTRAVI, Wegovy, HETLIOZ.
Industry payments across MD — which companies pay providers there.
